Pds biotechnology appoints seth van voorhees as chief financial officer

Florham park, n.j., dec. 09, 2020 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced the appointment of seth van voorhees, ph.d. as its new chief financial officer effective january 1, 2021.
PDSB Ratings Summary
PDSB Quant Ranking